Bulletin
Investor Alert

VBI Vaccines Inc.

NAS: VBIV

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 7, 2020, 7:56 p.m.

/zigman2/quotes/201705917/composite

$

4.23

Change

-0.02 -0.35%

Volume

Volume 37,099

Quotes are delayed by 20 min

/zigman2/quotes/201705917/composite

Previous close

$ 4.21

$ 4.25

Change

+0.04 +0.83%

Day low

Day high

$4.13

$4.44

Open

52 week low

52 week high

$0.47

$6.93

Open

Company Description

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like ...

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

74.22

Price to Book Ratio

2.79

Enterprise Value to Sales

61.65

Total Debt to Enterprise Value

0.12

Efficiency

Revenue/Employee

17,768.00

Income Per Employee

-438,504.00

Receivables Turnover

17.28

Total Asset Turnover

0.02

Liquidity

Current Ratio

1.57

Quick Ratio

1.54

Cash Ratio

1.49

Profitability

Gross Margin

-310.09

Operating Margin

-2,075.96

Pretax Margin

-2,467.94

Net Margin

-2,467.94

Return on Assets

-42.20

Return on Equity

-58.82

Return on Total Capital

-42.55

Return on Invested Capital

-54.78

Capital Structure

Total Debt to Total Equity

18.47

Total Debt to Total Capital

15.59

Total Debt to Total Assets

13.34

Long-Term Debt to Equity

0.93

Long-Term Debt to Total Capital

0.78

Officers and Executives

Name Age Officer Since Title
Mr. Jeffrey R. Baxter 57 2016 President, Chief Executive Officer & Director
Mr. Christopher McNulty 42 2018 CFO & Head-Business Development
Dr. David Evander Anderson 49 2016 Chief Scientific Officer
Dr. Francisco Diaz-Mitoma 64 2016 Chief Medical Officer
Ms. Nell Beattie 31 2015 Director-Corporate Development & IR

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/24/2020 Perceptive Advisors LLC
9,090,909   Acquisition at $1.1 per share. 9,999,999
10/04/2019 Francisco Diaz-Mitoma
Chief Medical Officer
40,000   Acquisition at $0.5 per share. 20,000
09/30/2019 Jeffrey R. Baxter
CEO, President; Director
150,000   Acquisition at $0.5 per share. 75,000
09/30/2019 Francisco Diaz-Mitoma
Chief Medical Officer
14,500   Acquisition at $0.5 per share. 7,250
09/23/2019 Perceptive Advisors LLC
20,000,000   Acquisition at $0.5 per share. 10,000,000
06/27/2019 Francisco Diaz-Mitoma
Chief Medical Officer
8,000   Acquisition at $1.07 per share. 8,560
06/20/2019 Francisco Diaz-Mitoma
Chief Medical Officer
42,000   Acquisition at $0.89 per share. 37,380
06/20/2019 Francisco Diaz-Mitoma
Chief Medical Officer
10,000   Acquisition at $0.78 per share. 7,800
06/19/2019 Jeffrey R. Baxter
CEO, President; Director
144,000   Acquisition at $0.73 per share. 105,120
06/19/2019 Nell Beattie
Chief Business Officer
8,000   Acquisition at $0.74 per share. 5,920
06/17/2019 Perceptive Advisors LLC
1,000,000   Acquisition at $0.62 per share. 620,000
06/14/2019 Jeffrey R. Baxter
CEO, President; Director
31,250   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 David Evander Anderson
Chief Scientific Officer
21,875   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Steven H. Gillis
Director
18,750   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Nell Beattie
Chief Business Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Michel de Wilde
Director
12,500   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2019 David Evander Anderson
Chief Scientific Officer
25,000   Award at $0 per share. 0
01/31/2019 Avi Mazaltov
Head Global MFG&GM-SciVac Ltd.
90,000   Award at $0 per share. 0
01/31/2019 Nell Beattie
Chief Business Officer
15,000   Award at $0 per share. 0
01/31/2019 Christopher McNulty
CFO and Head of BD
25,000   Award at $0 per share. 0
/news/latest/company/us/vbiv

MarketWatch News on VBIV

  1. VBI Vaccines stock price target raised to $5 from $4 at BMO Capital

    10:06 a.m. Jan. 10, 2020

    - Tomi Kilgore

  2. VBI Vaccines started at outperform with $3 stock price target at Raymond James

    8:52 a.m. Nov. 14, 2019

    - Tomi Kilgore

  3. Tegna, First United, Alico, and Other 13D Filings

    9:30 p.m. Oct. 4, 2019

    - Barron's Online

  4. Vintage Capital Takes Bite from Red Robin

    10:39 p.m. June 28, 2019

    - Barron's Online

  5. A Biotech Pro Loaded Up on These 2 Stocks

    7:30 a.m. June 23, 2019

    - Barron's Online

  6. 5 things to know about Hookipa Pharma ahead of its IPO

    7:26 a.m. April 18, 2019

    - Sarah Toy

  7. VBI Vaccines started at outperform with $9 stock price target at Oppenheimer

    10:15 a.m. Jan. 16, 2019

    - Tomi Kilgore

  8. VBI Vaccines started at outperform with $11 stock price target at BMO Capital

    10:35 a.m. Nov. 15, 2017

    - Tomi Kilgore

  9. Viex Sees Potential in Babcock & Wilcox

    11:12 p.m. Nov. 3, 2017

    - Barron's Online

  10. VBI Vaccines started at buy with $7 stock price target at Ladenburg Thalmann

    9:05 a.m. July 26, 2016

    - Tomi Kilgore

  11. A year after Lehman collapse, few execs resurface

    3:40 a.m. Sept. 8, 2009

    - Alistair Barr

  12. Doctor, Heal Thyself

    1:01 a.m. Nov. 27, 2006

    - Barron's Online

  13. Paulson Capital declares special 15c cash div

    4:24 p.m. Jan. 27, 2005

    - Heather Wilson

  14. Paulson Capital declares special 15c div

    4:21 p.m. Jan. 27, 2005

    - Heather Wilson

  15. Paulson Capital div record date on Feb. 10

    4:21 p.m. Jan. 27, 2005

    - Heather Wilson

  16. Paulson Capital Q3 rev $4.7M vs $12M

    3:34 p.m. Aug. 12, 2004

    - Heather Wilson

  17. Paulson Capital Q2 net loss 8c vs $1.91

    3:32 p.m. Aug. 12, 2004

    - Heather Wilson

  18. Paulson Capital Q1 net loss 11c vs $1.73

    1:24 p.m. May 13, 2004

    - Carla Mozee

  19. Paulson Capital Q3 net earns 70 cents vs 33 cents

    1:01 p.m. Nov. 12, 2003

    - Jenny Spitz

  20. Paulson Capital Q2 earns $1.91 vs $1.99 yr ago qtr

    1:48 p.m. Aug. 14, 2003

    - Jenny Spitz

  21. Loading more headlines...
/news/nonmarketwatch/company/us/vbiv

Other News on VBIV

  1. Timing the Market, Is it Possible? - August 07, 2020

    10:30 a.m. Aug. 7, 2020

    - Zacks.com

  2. VBI Vaccines rallies 11% on funding to advance COVID-19 vaccine

    10:33 a.m. Aug. 5, 2020

    - Seeking Alpha

  3. VBI Vaccines (VBIV) Gets a Buy Rating from Canaccord Genuity

    6:10 a.m. Aug. 3, 2020

    - SmarterAnalyst

  4. VBI Vaccines (VBIV) Received its Third Buy in a Row

    5:02 a.m. Aug. 3, 2020

    - SmarterAnalyst

  5. 10-Q: VBI VACCINES INC/BC

    8:59 a.m. July 31, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  6. VBI Vaccines (VBIV) to Report Q2 Earnings: What's in Store

    11:37 a.m. July 28, 2020

    - Zacks.com

  7. OPK, NBEV, DVAX and ACAD among midday movers

    12:39 p.m. July 21, 2020

    - Seeking Alpha

  8. NVAX, NBL among premarket gainers

    8:29 a.m. July 20, 2020

    - Seeking Alpha

  9. EU in talks with Moderna and others for COVID-19 vaccine supply

    9:06 a.m. July 17, 2020

    - Seeking Alpha

  10. Denovo Biopharma's enzastaurin Fast Track'd for brain tumor

    8:18 a.m. July 17, 2020

    - Seeking Alpha

  11. My COVID-19 Vaccine Report Card

    9:41 a.m. July 16, 2020

    - Seeking Alpha

  12. AAL, UAL among premarket gainers

    8:16 a.m. July 15, 2020

    - Seeking Alpha

  13. Stocks To Watch: Bank Earnings And SPAC Deals Blaze In

    8:25 a.m. July 11, 2020

    - Seeking Alpha

  14. BIIB, MFGP among premarket gainers

    8:17 a.m. July 8, 2020

    - Seeking Alpha

  15. NVAX, MFGP, RUN and TOPS among midday movers

    12:43 p.m. July 7, 2020

    - Seeking Alpha

  16. VBI Vaccines (VBIV) Gets a Buy Rating from BMO Capital

    3:04 p.m. June 29, 2020

    - SmarterAnalyst

  17. Loading more headlines...

At a Glance

VBI Vaccines, Inc.

222 3rd Street

Suite 2241

Cambridge, Massachusetts 02142

Phone

1 6178303031

Industry

-

Sector

-

Fiscal Year-end

12/2020

Revenue

$2.22M

Net Income

$-54.81M

Employees

125.00

/news/pressrelease/company/us/vbiv

Press Releases on VBIV

  1. Tuesday Sector Laggards: Computer Peripherals, Biotechnology Stocks

    12:04 p.m. July 28, 2020

    - MarketNewsVideo.com

  2. Tuesday Sector Laggards: Biotechnology, Drugs

    12:01 p.m. July 21, 2020

    - MarketNewsVideo.com

  3. Loading more headlines...
Link to MarketWatch's Slice.